Novel mRNA vaccine plus immunotherapy reduces melanoma relapse in phase 3 trial
Posted:
In 2022, about 330,000 people around the world were diagnosed with the skin cancer melanoma, with about 60,000 people dying from the condition.
On August 19, pharmaceutical companies Merck and Moderna announced the phase 3 clinical study results for an experimental therapy designed to help lower the recurrence rate in people with stage IIB-IV melanoma who have had their tumor completely removed.
OpenAI is expanding ChatGPT's healthcare capabilities with a new integration that connects Epic electronic health records (EHRs) to ChatGPT for Healthcare and a plugin that gives care providers access to public healthcare data sources.
The Epic integration lets clinicians bring patient information into…
Updated migraine prevention guidance incorporates calcitonin gene-related peptide (CGRP)-targeted therapies and places greater emphasis on individualized treatment selection based on patient priorities.
Preventive therapy should be offered to those with at least 4 migraine days per month, at least 4 moderate-to-severe headache days per…
Attendees
Sponsors and Exhibitors
Contact us